Pfizer Inc. (NYSE:PFE) Shares Bought by Concord Asset Management LLC VA

Concord Asset Management LLC VA lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 265.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 48,232 shares of the biopharmaceutical company's stock after purchasing an additional 35,021 shares during the period. Concord Asset Management LLC VA's holdings in Pfizer were worth $1,222,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $28,000. Bernard Wealth Management Corp. purchased a new stake in Pfizer during the fourth quarter valued at approximately $30,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of analyst reports. BMO Capital Markets decreased their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Redburn Atlantic decreased their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Bank of America increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. HSBC decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Finally, Jefferies Financial Group increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average price target of $28.55.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.12 during midday trading on Friday, reaching $24.47. The company's stock had a trading volume of 25,334,474 shares, compared to its average volume of 41,894,684. The firm has a market capitalization of $139.09 billion, a PE ratio of 17.72, a P/E/G ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a fifty day moving average of $24.02 and a 200 day moving average of $24.75. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.82 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.03%. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.